FigureĀ 3.
Kaplan-Meier estimates of survival outcomes in younger patients treated with intensive therapy. (A) RFS. (B) OS. (C) Impact of venetoclax added to intensive therapy on RFS. (D) Impact of venetoclax added to intensive therapy on OS. mOS, median OS; mRFS, median RFS; NAR, number at risk; Ven, venetoclax.